The study examined long-term therapy persistence with glatiramer acetate relative to other available disease-modifying therapies for multiple sclerosis.

Retrospective US Database Analysis of Persistence With Glatiramer Acetate vs. Available Disease-Modifying Therapies for Multiple Sclerosis: 2001–2010 ...

Retrospective US Database Analysis of Persistence With Glatiramer Acetate vs. Available Disease-Modifying Therapies for Multiple Sclerosis: 2001–2010 ...

Acetate is one short chain fatty acid (SCFA), and research has indicated that it can be beneficial to human health, along with other SCFAs. This group of researchers has previously developed a type of ...